Civetta Therapeutics
Assistant Professor of BCMP at Harvard Medical School and Dana-Farber Cancer Institute. He co-directs the DFCI Center for Protein Degradation, SAB member of C4 Therapeutics. His research focuses on understanding the complex mechanisms that underlie the function and regulation of multi-component ubiquitin ligases and their role in disease. Dr. Fischer has been recognized for his pioneering work on the structure of cereblon and the mechanism of action of thalidomide.
This person is not in the org chart
This person is not in any offices
Civetta Therapeutics
Civetta Therapeutics;s mission is to advance new medicines through small molecule intervention targeting propeller domains with the goal of developing important therapeutics for cancer and other indications.